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1 Despite the recently described reduction in incidence, the number of patients with dementia is estimated to triplicate by 2050 as a result of the aging of the world population and the lack of disease-modifying treatments.
1 Recent evidence suggests that hypertension contributes significantly to the development and progression of the 2 most common types of dementia: Alzheimer disease (AD) and vascular cognitive impairment-dementia (VaD). 2 However, it remained unclear whether it is the average blood pressure level or blood pressure variability (BPV) that is responsible for the cognitive decline. In this issue of Circulation, Oishi et al 3 provide new data strengthening the case that BPV is a key driver of the association with subsequent dementia, an effect that may be particularly relevant to AD.
Although blood pressure is often viewed as 2 simple numeric values, systolic blood pressure (SBP) and diastolic blood pressure (DBP), it is now well established that both SBP and DBP have marked oscillations in the short term (24 hours), midterm (days/weeks), and long term (years). 4 Historically, variability in blood pressure was viewed as an impediment for the accurate assessment of blood pressure recordings and as a phenomenon to be reconciled by improved monitoring; however, over the last 20 years, BPV has been recognized as an independent risk factor for cardiovascular disease. 4 Recently, several longitudinal studies have reported that increased long-term BPV, independent of the average blood pressure level, is associated with a higher risk of cognitive impairment and dementia (Table) . However, in most studies, BPV was assessed by mid-and long-term office measurements, which are subject to considerable bias, and the association between dementia subtypes and BPV assessed by daily measurement in blood pressure at home has not been evaluated.
Oishi et al 3 report findings from a prospective study of 1674 Japanese patients who were ≥60 years of age and without baseline dementia. The study assessed the association between home day-to-day BPV and the risk of incident all-cause dementia, VaD, and AD. All patients measured their blood pressure in the morning for a median of 28 days (range, 3-28 days) using an automated digital electronic blood pressure device. Day-to-day variations in both SBP and DBP were defined with the coefficient of variation (CoV), calculated as the SD of the mean blood pressure divided by the mean blood pressure times 100 and categorized into quartiles. Dementia diagnoses were adjudicated by neurologists or psychiatrists and were based on rigorous evaluation of clinical information, neuroimaging, or autopsy reports. During the 5-year follow-up period, 194 patients (11.6%) developed all-cause dementia, of whom 47 (2.8%) had VaD and 134 (8.0%) had AD. The age-and sex-adjusted incidences of all-cause dementia, VaD, and AD increased significantly with increasing CoV quartiles of home SBP (all P for trends <0.05). These associations remained unchanged after adjustment for demographics, risk factors for dementia, and mean SBP values. Compared with patients in the first quartile of CoV levels of home SBP, the risks of developing all-cause dementia, VaD, and AD were significantly higher in those in the fourth quartile for all-cause dementia (hazard ratio=2.27), for VaD (hazard ratio=2.79), and for AD (hazard ratio=2.22). Similar associations were observed for CoV levels of home DBP. Although there was no interaction between mean SBP and CoV levels of home SBP, mean home SBP was associated with the risk of VaD but not with the risk of AD. These results demonstrate a significant association between home day-to-day BPV and the risk of AD and VaD, independently of the average blood pressure level.
Although prior studies have demonstrated an association between cognitive decline and long-term BPV, assessed by monthly or yearly blood pressure measurements in the office, this approach is subject to a number of potential confounders such as variations of time of the day or season during which blood pressure was measured, differences among blood pressure machines or cuff sizes, changes in antihypertensive agents, accumulation of medical comorbidities, and the white coat effect. Given the limitations of long-term blood pressure monitoring, the results of Oishi et al, 3 based on day-today monitoring of blood pressure at home, add considerable strength to the association between higher BPV and dementia. Moreover, the majority of prior studies assessing the relationship between BPV and cognitive decline focused solely on patients' Mini-Mental State Examination scores and cognitive testing rather than formal diagnoses of dementia. [5] [6] [7] Such an approach is hypothesis generating but does not facilitate a mechanistic explanation underpinning the relationship between BPV and specific patterns of neurodegeneration. Previously, Alpérovitch et al 8 found a positive association between BPV and AD but found no such association for VaD. The study by Oishi et al is the first to find an independent association between BPV and both AD and VaD, suggesting that BPV plays an important role in the development of both AD and VaD subtypes. However, an important difference between AD and VaD was found: both higher BPV and higher mean SBP values were associated with VaD, but only higher BPV was associated with AD. These results indicate that, as opposed to the average blood pressure level, BPV may be a more useful indicator for the risk of subsequent AD and may represent a potential target for treatments designed to prevent the development of AD.
What are the potential mechanisms of the deleterious effects of BPV on cognitive function? Brain function is highly dependent on a constant and well-regulated blood supply matched to its dynamic energy needs. 9 Whereas complete interruption of blood flow leads to irretrievable brain damage, more subtle alterations in the cerebral blood supply, when sustained in time, lead to dysfunction and damage in susceptible brain regions, often associated with cognitive deficits. 9 The latter may be the case in the effects of BPV on the brain. BPV has been linked to oxidative stress, endothelial injury, impairment of vascular smooth muscle function, and vascular stiffening. 10 Therefore, BPV may promote dysregulation of the cerebral vasculature, which in turn causes a mismatch between the supply of energy substrates and the energy demands of the brain. The resulting alterations in the homeostasis of the cerebral microenvironment may lead to brain dysfunction and damage. 9 In addition, extreme variations in blood pressure may bypass cerebrovascular autoregulation, that is, the ability of the brain to keep cerebral perfusion relatively constant despite changes in blood pressure, and lead to potentially damaging fluctuations in blood flow. Indeed, higher BPV is associated with both macroscopic injury, including stroke, and microvascular injury, including cortical microbleeds and cerebral white matter hyperintensities. 4 Chronic hypertension may also promote the brain accumulation of amyloid, 11, 12 a pathological hallmark of AD. In this regard, the novel finding of a lack of association between average blood pressure level increases and AD 3 raises the possibility that BPV may be more likely to promote AD pathology. However, data linking specifically amyloid accumulation to BPV are currently lacking.
Certain limitations should be considered. First, although short-term blood pressure measurements are subject to less variation than long-term measurements, any time-limited aberration from baseline such as sickness, medication noncompliance, or inconsistent blood pressure measurement technique may have significantly affected the results of the study. Second, although use of an antihypertensive agent was included as a covariate, the authors did not account for the differential effect of certain antihypertensive agents on BPV. For example, calcium channel blockers and diuretics appear to have a stronger effect on reducing BPV than other antihypertensive medications. 13 Last, although no patient had dementia at the time of BPV measurement, it is possible that some patients had preexisting mild cognitive impairment. Therefore, higher BPV could be the consequence of a preexisting neurodegenerative process rather than a risk factor for dementia. Indeed, alteration of baroreceptor circuits, which may occur in AD, can result in BPV.
14 However, a factor mitigating this concern is that the results were unchanged after the exclusion of patients with a dementia diagnosis within 2 years of SBP measurement. 3 Whether BPV represents a modifiable dementia risk factor is unclear. Data from both the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) and Syst-Eur trials (Systolic Hypertension in Europe) indicate that reduction in the average blood pressure level is associated with a reduction in dementia. 2, 11 Because BPV was not measured in these trials, it is uncertain whether targeting reduction in BPV, rather than absolute SBP or DBP values, may lead to a further risk reduction in dementia incidence. Furthermore, late-life low blood pressure is also associated with dementia, 15 thus raising conflicting advice on how to best treat hypertension in the elderly, who have the greatest risk of developing dementia. Nevertheless, the novel findings of Oishi et al, 3 in concert with prior work, suggest that BPV, independent of the average SBP or DBP value, may be associated with the development of dementia. If confirmed in a larger cohort, these findings may guide future prospective studies aimed at curtailing the risk of dementia by reducing BPV.
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